BRD4 and lymphoma: In a Phase I clinical trial of the BRD4 inhibitor CC-90010 in 67 solid tumor and 2 lymphoma patients, one patient each with astrocytoma or endometrial carcinoma achieves a complete response or a partial response, and six additional patients experience prolonged stable disease [67].